Rhofade®

Drug - Rhofade® (oxymetazoline 1% cream) [Mayne Pharma Commercial, LLC.]

July 2025

Therapeutic Area - Rosacea Agents, Topical

Initial approval criteria

Patient is ≥ 18 years of age; AND
Patient has a diagnosis of persistent facial erythema associated with a diagnosis of rosacea; AND
Prescriber attests that if the patient has cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or
hypotension they will be appropriately monitored and will be counseled to seek medical care if their condition worsens; AND
Prescriber attests that patient with cerebral or coronary insufficiency, Raynaud's phenomenon, thromboangiitis obliterans, scleroderma, or Sjögren's syndrome will receive appropriate monitoring and advised to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop; AND
Prescriber attests that patient will receive counseling on the signs and symptoms of acute angle closure glaucoma and will be advised to seek immediate care if they develop; AND
Prescriber has reviewed Rhofade drug interactions and will monitor patient status as appropriate

Patient must continue to meet the above criteria; AND
Patient has experienced improvement or resolution of facial erythema associated with rosacea; AND
Patient has NOT experienced any treatment-restricting adverse effects.

Provider Call Center (844) 575-7887